一名男孩因费城染色体阳性的急性淋巴细胞白血病并伴有骨溶解，通过酪氨酸激酶抑制剂安全治疗。
A Boy Safely Treated with Tyrosine Kinase Inhibitors for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Osteolysis.
发表日期：2023 Aug
作者：
Takahiro Shiwaku, Hisashi Ishida, Yasuhisa Tatebe, Kosuke Tamefusa, Motoharu Ochi, Kaori Fujiwara, Toshihide Kubo, Eiji Nakata, Kana Washio, Hirokazu Tsukahara
来源：
Acta medica Okayama
摘要：
一名患有费城染色体阳性B细胞前体急性淋巴细胞白血病（Ph+ALL）的三岁男童右上臂出现溶骨性病变。酪氨酸激酶抑制剂（TKI）如伊马替尼和达沙替尼在Ph+ALL的整个治疗过程中是必不可少的组成部分。然而，据报道，TKI可能会影响骨代谢。在当前患者的治疗过程中，尽管持续使用TKI，甚至同时使用皮质类固醇，溶骨性病变迅速改善。这表明，在存在溶骨性病变的Ph+ALL儿童中，TKI可以安全地与皮质类固醇同时使用。
A three-year-old boy with Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ALL) presented with an osteolytic lesion in his right upper arm. Tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib are an essential component throughout the course of treatment for Ph+ALL. However, TKIs are reported to affect the bone metabolism. In the treatment course of the current patient, the osteolytic lesion quickly improved despite the continuous use of TKIs, even during the concomitant use of corticosteroids. This suggests that TKIs can be safely given with concomitant corticosteroids to children with Ph+ALL, even when osteolytic lesions are present.